N4-(2-methoxyphenyl)benzene-1,4-diamine profile

ID Source	ID
PubMed CID	2369091
CHEMBL ID	1310702
CHEBI ID	112237
SCHEMBL ID	1618638

Synonym
n-(2-methoxy-phenyl)-benzene-1,4-diamine
ENAMINE_001862
OPREA1_311693
smr000352481
MLS001007260
CHEBI:112237
AKOS000115597
HMS1399E14
4-n-(2-methoxyphenyl)benzene-1,4-diamine
HMS2722L08
CHEMBL1310702
EN300-02103
5840-11-9
n1-(2-methoxyphenyl)benzene-1,4-diamine
SCHEMBL1618638
1-n-(2-methoxyphenyl)benzene-1,4-diamine
Q27192339
n4-(2-methoxyphenyl)benzene-1,4-diamine
sr-01000031876
SR-01000031876-1
DTXSID20368290
n~1~-(2-methoxyphenyl)benzene-1,4-diamine
n-(2-methoxyphenyl)benzene-1,4-diamine
Z56821894
SB79171

Class	Description
aromatic ether	Any ether in which the oxygen is attached to at least one aryl substituent.
substituted aniline
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolase	Giardia intestinalis	Potency	17.7407	0.1409	11.1940	39.8107	AID2451
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	50.1187	0.6310	35.7641	100.0000	AID504339
ATAD5 protein, partial	Homo sapiens (human)	Potency	20.5878	0.0041	10.8903	31.5287	AID504467
GLS protein	Homo sapiens (human)	Potency	11.2202	0.3548	7.9355	39.8107	AID624170
Microtubule-associated protein tau	Homo sapiens (human)	Potency	27.8298	0.1800	13.5574	39.8107	AID1460; AID1468
thioredoxin glutathione reductase	Schistosoma mansoni	Potency	50.1187	0.1000	22.9075	100.0000	AID485364
Smad3	Homo sapiens (human)	Potency	22.3872	0.0052	7.8098	29.0929	AID588855
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	28.1838	0.0112	12.4002	100.0000	AID1030
bromodomain adjacent to zinc finger domain 2B	Homo sapiens (human)	Potency	28.1838	0.7079	36.9043	89.1251	AID504333
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	12.5893	0.0355	20.9770	89.1251	AID504332
chromobox protein homolog 1	Homo sapiens (human)	Potency	56.2341	0.0060	26.1688	89.1251	AID540317
mitogen-activated protein kinase 1	Homo sapiens (human)	Potency	28.1838	0.0398	16.7842	39.8107	AID1454
lethal(3)malignant brain tumor-like protein 1 isoform I	Homo sapiens (human)	Potency	39.8107	0.0752	15.2253	39.8107	AID485360
geminin	Homo sapiens (human)	Potency	23.1093	0.0046	11.3741	33.4983	AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay ID	Title	Year	Journal	Article
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	4 (66.67)	24.3611
2020's	1 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1

N4-(2-methoxyphenyl)benzene-1,4-diamine

Cross-References

Synonyms (25)

Drug Classes (2)

Protein Targets (14)

Potency Measurements

Bioassays (14)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.35

Study Types

N4-(2-methoxyphenyl)benzene-1,4-diamine

Cross-References

Synonyms (25)

Drug Classes (2)

Protein Targets (14)

Potency Measurements

Bioassays (14)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.35

Study Types

Related Conditions (4)